IgA Kidney Disease Trial Shows Promise in Phase 3 Interim Results

Researchers have released early results from the RAINIER AIS-D08 trial, which is testing a drug called povetacicept in people with IgA nephropathy (a condition where the immune system damages the kidneys’ tiny filtering units, causing them to leak protein and blood into the urine). The findings were presented at the American Society of Nephrology’s Kidney Week conference and published in the New England Journal of Medicine.

IgA nephropathy is one of the most common forms of kidney disease worldwide. Without effective treatment, it can progress slowly to kidney failure over years or decades.

Povetacicept works by blocking two proteins — APRIL and BAFF — that drive the abnormal immune response behind the disease. The interim analysis covers data from the ongoing phase 3 trial, meaning the full results are not yet available and the treatment has not been approved for routine use.

The findings are described as interim, so conclusions about long-term safety and effectiveness will depend on the completed trial data.

—

*IgA nephropathy is diagnosed through a kidney biopsy (a small tissue sample taken from the kidney). People with symptoms such as persistent blood in the urine, foamy urine, swollen ankles or high blood pressure should speak to their GP. NHS 111 is available around the clock for urgent health queries. In an emergency, call 999.*

—

Key information

• IgA nephropathy symptoms include blood in the urine, foamy urine and ankle swelling — speak to your GP if concerned
• This treatment is not yet approved or available on the NHS; the trial is ongoing
• For non-emergency health queries, contact NHS 111 (call 111 or use the online service)
• For kidney disease support and information, the National Kidney Federation helpline is available on 0800 169 0936